| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.14▼ | 2.15▼ | 2.15▼ | 2.11▲ | 2.16▼ |
| MA10 | 2.14▼ | 2.15▼ | 2.13▲ | 2.13▲ | 2.30▼ |
| MA20 | 2.15▼ | 2.12▲ | 2.11▲ | 2.18▼ | 2.40▼ |
| MA50 | 2.13▲ | 2.13▲ | 2.13▲ | 2.33▼ | 2.46▼ |
| MA100 | 2.13▲ | 2.13▲ | 2.17▼ | 2.46▼ | 3.74▼ |
| MA200 | 2.13▲ | 2.21▼ | 2.28▼ | 2.47▼ | 7.67▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.003▼ | 0.003▲ | 0.007▲ | 0.003▲ | -0.036▼ |
| RSI | 45.700▼ | 51.181▲ | 51.616▲ | 43.807▼ | 39.819▼ |
| STOCH | 20.556 | 63.462 | 82.022▲ | 37.466 | 14.268▼ |
| WILL %R | -71.429 | -37.500 | -33.333 | -65.000 | -87.186▼ |
| CCI | -168.794▼ | -5.292 | 40.709 | -4.450 | -106.375▼ |
|
Tuesday, November 17, 2026 05:30 AM
In a post hoc analysis of patients ≥65 years from the positive Phase 2b QUALITY study, those on semaglutide + placebo lost significant lean mass and had reduced stair climb power and slower stair ...
|
|
Monday, November 09, 2026 12:30 AM
Evaluating enobosarm in combination with GLP-1 RA for higher quality weight reduction in older patients with obesity ...
|
|
Thursday, June 04, 2026 07:22 AM
Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/11/26 | 2.14 | 2.18 | 2.115 | 2.135 | 304,970 |
| 16/11/26 | 2.08 | 2.14 | 2.03 | 2.08 | 198,904 |
| 13/11/26 | 2.15 | 2.15 | 2.08 | 2.09 | 90,525 |
| 12/11/26 | 2.10 | 2.15 | 2.0792 | 2.12 | 91,575 |
| 11/11/26 | 2.13 | 2.17 | 2.0709 | 2.14 | 38,943 |
| 10/11/26 | 2.17 | 2.21 | 2.06 | 2.12 | 128,465 |
| 09/11/26 | 2.12 | 2.21 | 2.105 | 2.19 | 134,426 |
| 06/11/26 | 2.08 | 2.15 | 2.06 | 2.12 | 137,100 |
| 05/11/26 | 2.20 | 2.20 | 2.04 | 2.06 | 216,132 |
| 04/11/26 | 2.18 | 2.23 | 2.10 | 2.20 | 180,500 |
|
|
||||
|
|
||||
|
|